ORPHA:97290
Familial papillary thyroid carcinoma with renal papillary neoplasia
Also known as: PTC-RCC
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
10
21.7th percentile
Trials
0
Interventional, condition-specific
Researchers
64
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
An extremely rare inherited tumor syndrome within the familial nonmedullary thyroid cancer group.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011578
- MeSH:C565310
- OMIM:605642
- UMLS:C1854104
Additional Mondo synonyms (1)
ptc-RCC
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
10 matched papers (6 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
10
10 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
10 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
6 in the last 10 years · high confidence · 21.7th percentile (publications denominator)
Phrase hits: 10 · MeSH hits: 0
Who's working on it?
64
Distinct author names in 10 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Ardini E1 paper · 2013Papers in Europe PMC
- 02Asnani A1 paper · 2017
1Cardio-Oncology Program, Corrigan Minehan Heart Center, Massachusetts General Hospital, 149 13th Street, Room 4.302, Boston, MA 02129 USA.
Papers in Europe PMC - 03Bandgar T1 paper · 2021
Department of Endocrinology, Seth G.S Medical College and KEM Hospital, Parel, Mumbai, Maharashtra, 4000012, India. drtusharb@gmail.com.
Papers in Europe PMC - 04Berlingieri MT1 paper · 1996Papers in Europe PMC
- 05Borrello MG1 paper · 2013
UO Molecular Mechanisms, Experimental Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via GA. Amadeo, 42-20133 Milano, Italy. mariagrazia.borrello@istitutotumori.mi.it
Papers in Europe PMC - 06Carlomagno F1 paper · 1996
Centro di Endocrinologia ed Oncologia Sperimentale del CNR, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università di Napoli, Italy.
Papers in Europe PMC - 07Carty SE1 paper · 2022
Division of Endocrine Surgery, Department of Surgery; and Department of Pathology; University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Papers in Europe PMC - 08Cheng G1 paper · 2021
Department of Physiology, Stein Eye Institute, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA. chengguo@ucla.edu.
Papers in Europe PMC - 09Chiosea SI1 paper · 2022
Division of Molecular and Genomic Pathology, Department of Pathology; Department of Pathology; University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Papers in Europe PMC - 10Chuang YC1 paper · 2026
Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Rd, Taipei City, 112201, Taiwan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Familial papillary thyroid carcinoma with renal papillary neoplasia" OR "PTC-RCC"
MeSH descriptor terms unioned into the query: Thyroid Carcinoma, Papillary, With Papillary Renal Neoplasia
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Familial papillary thyroid carcinoma with renal papillary neoplasia" OR "PTC-RCC" OR "Thyroid Carcinoma, Papillary, With Papillary Renal Neoplasia"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T05:09:28.888Z